RxDoctor Payments DataLook up a doctor →

Michael Aaronson, MD

Nephrology · Lincoln, NENPI 1326014028

Payments from drug & device makers

$498,419in general payments, 2019–2025

Across 864 payments — averaging $576.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$138K
  • Boehringer Ingelheim$110K
  • Lilly USA, LLC$87K
  • AstraZeneca$62K
  • Bayer$36K
  • Novo Nordisk$35K
  • plus $31K from 27 others

What the payments were for

  • Consulting fees$6,4801%
  • Speaking & faculty fees$461,57393%
  • Travel & lodging$16,6803%
  • Food & beverage$13,4023%
  • Education$2850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$498,419 in reported general payments places this provider in the 95th percentile of 60 nephrology providers in Nebraska.

See all nephrology providers in Nebraska

Medicare billing

Part B allowed, 2024
$463,127
Medicare patients
897
Services billed
7,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin565$585,365
FarxigaDapagliflozin Propanediol218$241,986
OzempicSemaglutide68$64,310
LokelmaSodium Zirconium Cyclosilicate27$11,919
VeltassaPatiromer Calcium Sorbitex12$10,802
Sevelamer Carbonate30$8,636
Potassium Citrate ErPotassium Citrate57$8,169
Torsemide317$6,188
InvokanaCanagliflozin11$6,028
Spironolactone805$3,911
Potassium Chloride55$3,279
Losartan Potassium335$2,379
Midodrine Hcl20$2,220
Irbesartan161$2,055
Carvedilol263$1,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$110,253$585,365565 claims
AstraZenecaFarxiga, Lokelma$61,763$253,905245 claims
Novo NordiskOzempic$34,530$64,31068 claims
Johnson & JohnsonInvokana$27$6,02811 claims
ANI Pharmaceuticals, Inc.Valsartan$121$49118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 nephrology providers in Nebraska.

Other nephrology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →